Europe Hereditary Angioedema Therapeutics Market Size & Outlook
Related Markets
Europe hereditary angioedema therapeutics market highlights
- The Europe hereditary angioedema therapeutics market generated a revenue of USD 1,000.3 million in 2025.
- The market is expected to grow at a CAGR of 11.1% from 2026 to 2033.
- In terms of segment, kallikrein inhibitor was the largest revenue generating treatment in 2025.
- Kallikrein inhibitor is the most lucrative treatment segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 1,000.3 million |
| Market revenue in 2033 | USD 2,392.7 million |
| Growth rate | 11.1% (CAGR from 2026 to 2033) |
| Largest segment | Kallikrein inhibitor |
| Fastest growing segment | Kallikrein inhibitor |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C1-Inhibitor Concentrates, Bradykinin B2 receptor antagonist, Kallikrein inhibitor |
| Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
Other key industry trends
- In terms of revenue, Europe region accounted for 27.8% of the global hereditary angioedema therapeutics market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,045.0 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hereditary Angioedema Therapeutics Market Scope
Hereditary Angioedema Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Attune Pharmaceuticals | View profile | 1-10 | New York, New York, United States, North America | http://attunepharma.com/ |
| Pharming Group | View profile | 382 | Darwinweg 24, Leiden, ZH, Netherlands, 2333 CR | https://www.pharming.com |
| KalVista Pharmaceuticals Inc | View profile | 118 | 55 Cambridge Parkway, Suite 901 East, Cambridge, MA, United States, 02142 | https://www.kalvista.com |
| Adverum Biotechnologies Inc | View profile | 121 | 100 Cardinal Way, Redwood CIty, CA, United States, 94063 | https://www.adverum.com |
| BioCryst Pharmaceuticals Inc | View profile | 531 | 4505 Emperor Boulevard, Suite 200, Durham, NC, United States, 27703 | https://www.biocryst.com |
| Ionis Pharmaceuticals Inc | View profile | 927 | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 | https://www.ionispharma.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
Europe hereditary angioedema therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 53.44% in 2025. Horizon Databook has segmented the Europe hereditary angioedema therapeutics market based on c1-inhibitor concentrates, bradykinin b2 receptor antagonist, kallikrein inhibitor covering the revenue growth of each sub-segment from 2021 to 2033.
Europe is anticipated to grow at significant growth over the forecast period. An increase in research funding and the local presence of key market players in this region are expected to drive the market. Progress in understanding the disease process has resulted in the recent availability of a broader range of HAE treatment options in the region.
Disease management consists of treating acute attacks, providing short-term prophylactic treatment to prevent attacks, and providing long-term prophylactic treatment to reduce the frequency and severity of ongoing attacks.
Plasma-derived C1-inhibitor concentrate (Cetor, Berinert), pd nano-filtered C1-inhibitor (Cinryze), recombinant C1-inhibitor (Rhucin/Ruconest), and a bradykinin B2 receptor antagonist (Firazyr) are currently approved in Europe for acute attacks.
Reasons to subscribe to Europe hereditary angioedema therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe hereditary angioedema therapeutics market databook
-
Our clientele includes a mix of hereditary angioedema therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe hereditary angioedema therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into Europe hereditary angioedema therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Europe hereditary angioedema hae therapeutics market size, by country, 2021-2033 (US$M)
Europe Hereditary Angioedema Therapeutics Market Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
